Healthcare Utilization and Costs Among Hereditary Angioedema Patients Receiving Long-Term Prophylaxis: Results of a Claims Database Analysis
Barriers to Timely On-Demand Treatment of Hereditary Angioedema Attacks in Italian Patients
Efficacy and Safety of Sebetralstat for On-demand Treatment of Hereditary Angioedema in Pooled Analysis of Placebo-controlled Clinical Trials
Barriers to Timely On-Demand Treatment of Hereditary Angioedema Attacks in Italian Patients
Burden of Injectable On-Demand Treatment for Hereditary Angioedema Attacks in Adolescents
Delays in the On-Demand Treatment of Hereditary Angioedema Attacks and Associated Barriers Reported in Different Healthcare Systems
Effectiveness of Sebetralstat for the On-demand Treatment of Laryngeal Hereditary Angioedema Attacks: Interim Analysis from KONFIDENT-S
On-demand Treatment Of Hereditary Angioedema Attacks With Sebetralstat In Adolescents: Pooled Analysis From KONFIDENT And KONFIDENT-S
Study to Adjudicate Hereditary Angioedema with Normal C1INH Diagnoses in the PIONEER-HAE Database
Impact of Long-Term Prophylaxis Adherence in Hereditary Angioedema Patients: Results of a Claims Database Analysis
Safety and Effectiveness of Sebetralstat in Patients with Hereditary Angioedema Receiving Long-term Prophylaxis: Interim Analysis from the KONFIDENT-S Open-label Study
Sebetralstat for Treatment of Hereditary Angioedema Attacks in Patients Receiving Berotralstat: Interim Analysis from the KONFIDENT-S Open-label Study
Efficacy and Safety of Sebetralstat for On-demand Treatment of Hereditary Angioedema in Pooled Analysis of Placebo-controlled Clinical Trials
Patrick Yong, Jonathan Bernstein, Danny Cohn, Henriette Farkas, William Lumry, Marc Riedl, Andrea Zanichelli, James Hao, Michael Smith, Christopher Yea, Paul Audhya, Emel Aygoren-Pursun, Sinisa Savic, Sorena Kiani-Alikhan Presented at British Society for Immunology Clinical Immunology Professional Network (BSI-CIPN) Conference; December 9-10, 2024; Birmingham, United Kingdom
Impact of Delayed Treatment of Hereditary Angioedema Attacks on Quality of Life and Ability to Work
Impact of Hereditary Angioedema Attacks on Quality of Life and Ability to Work Among UK Patients Receiving Long-term Prophylaxis or On-demand Only
Correlation of Time to Treatment with Attack Duration in the Sebetralstat KONFIDENT Phase 3 Trial
Indirect Treatment Comparison of Oral Sebetralstat and Intravenous rhC1-INH as On-demand Treatments for Hereditary Angioedema
On-demand Treatment of Laryngeal Hereditary Angioedema Attacks with Sebetralstat: Pooled Analysis from KONFIDENT and KONFIDENT-S
Patient-Reported Anxiety Impacts Utilization of Injectable On-demand Treatment of Hereditary Angioedema Attacks
Substantial Reduction of Hereditary Angioedema Attack Symptom Burden in the Sebetralstat Phase 3 KONFIDENT Trial
Real World Barriers to On-Demand Treatment for Attacks in Hereditary Angioedema: A Patient Survey
Anxiety Associated with Parenteral On-Demand Treatment for Hereditary Angioedema Attacks
Global Frequency and Diagnosis of Hereditary Angioedema with Normal C1INH: A Real World ACARE Survey
Impact of Oral Sebetralstat on Hereditary Angioedema Attack-associated Anxiety: Analysis From the Phase 3 KONFIDENT Trial
KONFIDENT Trial of Oral Sebetralstat for Treatment of Hereditary Angioedema Attacks: Analysis of the European and US Patient Populations
Delayed On-demand Treatment of Hereditary Angioedema Attacks: Italian Patient Perceptions and Associated Barriers
A Specific, Sensitivity Assay Measuring Patient Sample Plasma Kallikrein Activity
Delayed On-demand Treatment of Hereditary Angioedema Attacks and Associated Barriers Reported by Italian Patients
KONFIDENT-S Interim Analysis: Sebetralstat for Hereditary Angioedema Attacks Including Laryngeal
Pooled Sebetralstat Placebo-controlled Efficacy for On-demand Treatment of Hereditary Angioedema
Pooled Sebetralstat Placebo-controlled Safety for On-demand Treatment of Hereditary Angioedema
Anxiety Associated with On-demand Treatment of Hereditary Angioedema (HAE) Attacks
Attack Characteristics in Patients with Hereditary Angioedema Receiving Non-Androgen Long-term Prophylaxis
Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers
Hereditary Angioedema (HAE) Patients Answer: Why Do Attacks Go Untreated?
Patient-Reported Benefits of Early On-Demand Treatment of HAE Attacks
Sebetralstat as Oral On-demand Treatment for Hereditary Angioedema: Interim Analysis of the Open-label KONFIDENT-S Trial
Treatment of HAE Attacks with Anticipated Future Oral On-Demand Therapies as Reported by Patients
Unmet Needs Associated with Non-androgen Injectable Long-term Prophylaxis (LTP) Therapies for HAE
Burden of Untreated Hereditary Angioedema Attacks and its Impact on Social, Mental, and Physical Health
Healthcare Costs Among Commercially-Insured Patients with Hereditary Angioedema Managed with Long-Term Prophylaxis: A Retrospective US Claims Database Analysis
Real-World Impact of Treated Hereditary Angioedema Attacks on Patients’ Employment and Work Productivity
Real-World Impact of Treated Hereditary Angioedema Attacks on Patients’ Quality of Life
Sebetralstat for On-demand Treatment of Hereditary Angioedema Attacks: US Subgroup Analysis from the Double-blind, Placebo-controlled Phase 3 KONFIDENT Trial
Trends in Volume of On-demand Hereditary Angioedema Treatments in the US: A Retrospective Analysis of a Large Multi-payer Claims Database
Factor XIIa Inhibition Protects Against VEGF-Induced Neuroretinal Dysfunction in Mice
Healthcare Costs Among Commercially-Insured Patients with Hereditary Angioedema Managed with Long-Term Prophylaxis: A Retrospective US Claims Database Analysis
Relationship Between Time to On-demand Treatment and Quality of Life During Hereditary Angioedema Attacks
Anxiety Associated with On-demand Treatment of Hereditary Angioedema (HAE) Attacks
Anxiety Associated with Refilling On-demand Therapy for HAE Attacks Contributes to Treatment Delay and Non-Treatment
Characteristics of Hereditary Angioedema Attacks Among Long-term Prophylaxis Users
Characterizing the Negative Impact of Delayed On-Demand Treatment of HAE Attacks
Characterizing the Perspectives of Patients with HAE on Prophylactic Treatment
Delayed Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers
The Impact of On-demand Treatment on Quality of Life of People with HAE
Burden of Hereditary Angioedema Attacks in Adolescents
Quality of Life Among Prophylaxis Plus On-Demand and On-Demand Only Therapy Users in HAE
Anxiety Associated with On-demand Treatment of Hereditary Angioedema (HAE) Attacks May Result in Sub-optimal Attack Management
Understanding Why Hereditary Angioedema Patients Often Do Not Carry Their On-Demand Treatment with Them
KONFIDENT Phase 3 Trial Global Expansion: Sebetralstat Pharmacokinetics and Pharmacodynamics in Japanese and Chinese Adults
Reporting of Administration Site Reactions with Parenteral Drugs for the On-demand Treatment of Hereditary Andioedema Attacks – Analysis of the FAERS Database 2009 – 2022
The Discovery of Sebetralstat, an Oral, Small Molecule Plasma Kalkrein Inhibitor to Treat Attacks of Hereditary Angioedema
In Their Own Words – Patients Descriptions of the Earliest Recognition of Hereditary Angioedema Attack Onset
Preferences of People with Hereditary Angioedema for On-demand Treatment: A US Based Qualitative Study
Recognizing the Importance of Early On-demand Treatment in the Hereditary Angioedema (HAE) Attack Journey
Patients Delay Treating Hereditary Angioedema (HAE) Attacks with Currently Available, Injectable, On-demand Therapies
Remaining Burden of Hereditary Angioedema (HAE) Attacks Despite Modern Long-term Prophylaxis
Results From a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial Evaluating Sebetralstat Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability in Healthy Japanese, Chinese, and White Adults
Short-term Prophylaxis with Sebetralstat, an Investigational On-demand Treatment for Hereditary Angioedema, in KONFIDENT-S
Understanding the Complex Decision-Making Associated with On-Demand Treatment of Hereditary Angioedema (HAE) Attacks
Sebetralstat Effectiveness in the Treatment of Hereditary Angioedema Attacks Rated Mild or Moderate at Baseline in the Phase 2 Trial
HAE Patients’ Decision to Carry On-demand Treatment When Away from Home
Rationale for the Short-term Prophylaxis Regimen with Sebetralstat in KONFIDENT-S
Route of Administration Preferences of People Living with Hereditary Angioedema for On-demand Treatment: A US Based Qualitative Study
Anxiety Associated With Parenteral On-demand Treatment For Hereditary Angioedema (HAE)
Comparative Bioavailability of Sebetralstat Following Administration of Orally Disintegrating Tablets and Film-Coated Tablets in Healthy Volunteers
Treatment with Sebetralstat Reduces the Cumulative Symptom Severity of Hereditary Angioedema Attacks in a Phase 2 Trial
Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients with Hereditary Angioedema
Pharmacokinetic, Pharmacodynamic, and Safety Profile in Healthy Japanese and White Adults: Results from Phase 1, Randomized, Double-blind, Placebo-controlled Trial
Targeted Literature Review to Assess the Studies Supporting Short-term Prophylactic Treatment Options for the Preprocedural Prevention of Attacks in Patients with Hereditary Angioedema
Patient Perspectives on an Optimal Outcome Measure to Assess Efficacy in the Acute Treatment of Hereditary Angioedema Attacks
Population Pharmacokinetic Analysis of Sebetralstat (KVD900) in Healthy Volunteers and Patients with Hereditary Angioedema Predicts Similar Exposure in Adolescent Patients
Agreement Between Improvements in Patient Global Assessment of Change and Other Measures of Improvement and Attack Resolution Observed in a Phase 2 Trial with Sebetralstat (KVD900) in Patients with Hereditary Angioedema
Agreement of Patient Global Assessment of Change With Attack Resolution or Use of Rescue Medication in Patients with Hereditary Angioedema
